Persistent risk for new, subsequent new and recurrent hepatocellular carcinoma despite successful anti-hepatitis B virus therapy and tumor ablation: The need for hepatitis B virus cure.

Shinn, Brianna J; Martin, Aaron; Coben, Robert M; Conn, Mitchell I; Prieto, Jorge; Kroop, Howard; DiMarino, Anthony J; Hann, Hie-Won

Shinn, Brianna J; Martin, Aaron; Coben, Robert M; Conn, Mitchell I; Prieto, Jorge; Kroop, Howard; DiMarino, Anthony J; Hann, Hie-Won.

Afiliação

Shinn BJ; Division of Gastroenterology and Hepatology, Department of Medicine, Thomas Jefferson University Hospital, Philadelphia, PA 19107, United States.
Martin A; Division of Gastroenterology and Hepatology, Department of Medicine, Thomas Jefferson University Hospital, Philadelphia, PA 19107, United States.
Coben RM; Division of Gastroenterology and Hepatology, Department of Medicine, Thomas Jefferson University Hospital, Philadelphia, PA 19107, United States.
Conn MI; Division of Gastroenterology and Hepatology, Department of Medicine, Thomas Jefferson University Hospital, Philadelphia, PA 19107, United States.
Prieto J; Division of Gastroenterology and Hepatology, Department of Medicine, Thomas Jefferson University Hospital, Philadelphia, PA 19107, United States.
Kroop H; Division of Gastroenterology and Hepatology, Department of Medicine, Thomas Jefferson University Hospital, Philadelphia, PA 19107, United States.
DiMarino AJ; Division of Gastroenterology and Hepatology, Department of Medicine, Thomas Jefferson University Hospital, Philadelphia, PA 19107, United States.
Hann HW; Division of Gastroenterology and Hepatology, Department of Medicine, Thomas Jefferson University Hospital, Philadelphia, PA 19107, United States. hie-won.hann@jefferson.edu.

World J Hepatol ; 11(1): 65-73, 2019 Jan 27.

Article em En | MEDLINE | ID: mdl-30705719